You're not ramping. You're making a sensible reasoned argunent and joining dots.
As for the melanoma preclinical, you're correct. Why would RAC try Zantrene with only one PD-1(L) inhibitor? RAC would try Zantrene with all of them, most likely one at a time, but maybe also with more than one at a time
So the next question is when this part of the melanoma preclinical will read out? Sounds complex, need to trial firstly Zantrene, measure tumour response, then the combinations, measure tumour response. I'm guessing roughly Q3 next year.
- Forums
- ASX - By Stock
- RAC
- Ann: First Patient Dosed in Phase 1b/2 AML Trial
Ann: First Patient Dosed in Phase 1b/2 AML Trial, page-175
-
-
- There are more pages in this discussion • 71 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.56 |
Change
0.010(0.65%) |
Mkt cap ! $265.8M |
Open | High | Low | Value | Volume |
$1.55 | $1.56 | $1.51 | $95.69K | 62.25K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 3015 | $1.55 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.56 | 4018 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 3015 | 1.550 |
2 | 17973 | 1.530 |
1 | 19190 | 1.525 |
1 | 20000 | 1.520 |
1 | 500 | 1.500 |
Price($) | Vol. | No. |
---|---|---|
1.560 | 4018 | 1 |
1.570 | 4602 | 2 |
1.580 | 15715 | 3 |
1.600 | 2319 | 1 |
1.645 | 10000 | 1 |
Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
RAC (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online